STAAR Surgical Company (NASDAQ:STAA) Q4 2019 Earnings Conference Call - Final Transcript
Feb 26, 2020 • 04:30 pm ET
Thank you. [Operator Instructions] Your first question comes from Jason Mills with Canaccord Genuity. Your line is open.
Hi, great, thanks. Caren, can you hear me okay? [Indecipherable]
Yes, I can hear you, Jason.
Okay, great. Again, congratulations on a great year.
First, wanted to start with coronavirus. Thank you so much for the color. I guess the question is the $5 million to $7 million makes sense at this point given the uncertainty to us, but I guess over what time period do you expect these sales or these procedures to be done and how will you account for them. So, let's say that it's mostly felt in the first quarter and they come back perhaps over Q2, Q3 time frame. Will you be able to call that incremental revenue out -- the incremental revenue upside that you saw offset to the downside during this crisis?
Bottom line is, we had already planned contributions from each of our major markets on a quarterly basis. And as you know, it's always been split 22%, then 27%, I believe 26%, and 25%. So, what we're doing now is we're taking a look at the number of units that we didn't realize in February, and we've already actually received orders from customers to our distributor for shipment as soon as they reopen. So, we're already seeing what we call that kind of held back robust interest in getting back to work in a big way.
So, in answer to your question when we -- or next on the call or when we have visibility we feel it's important to share, we'll talk about how the spread will be. My expectation based on talking to our team, and the customer is they are going to work very, very hard, very aggressively and a lot of over time to get back on track to what they had planned for their year. I just want to remind everyone that they have budgets that they need to meet. They have employees they need to pay. They are in a very, let's say, recovery mindset to get back to work and get back on their own income statements in the right way from the smallest practice to the largest hospital.
Great. That's loud and clear. My second question, let's talk clinical, Caren, if you can for second. Could you talk about the approval timing? You mentioned DEKRA is still evaluating. Is this in line with your expectations, and I guess, maybe talk a little bit about your -- more color on the planned roll-out, the phased roll-out. And then in the United States, can you give us an update on pace of enrollment. I guess is it -- it's probably sort of more yesterday than the day before, so on and so forth, but could you give us an update on how that's going? Thank you.
Sure. So our phased roll-out is designed to make sure that those who have participated with us as principal investigators,